| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
N-Acetylcytisine targets nicotinic acetylcholine receptors (nAChRs), where it acts as a partial agonist. By binding to these receptors, it modulates their activity. This mechanism is similar to that of cytisine, which is used as a smoking cessation aid. The acetylation of cytisine may modify its binding affinity and pharmacokinetic properties compared to the parent compound.
|
|---|---|
| ln Vitro |
In vitro, N-Acetylcytisine interacts with nicotinic acetylcholine receptors as a partial agonist. Specific binding affinities (Ki or IC50 values) are not detailed in the available literature. As an alkaloid derivative of cytisine, it is expected to have similar but potentially distinct receptor binding properties. The compound is used in research on nicotinic receptor pharmacology and smoking cessation.
|
| ln Vivo |
Specific in vivo data for N-Acetylcytisine are not reported. Given its potential use in smoking cessation as a partial agonist at nicotinic acetylcholine receptors, the compound would have potential for in vivo studies in animal models of nicotine addiction and withdrawal. However, specific published in vivo protocols for this compound are not available.
|
| Enzyme Assay |
The nicotinic acetylcholine receptor binding affinity is assessed using radioligand binding assays. Membrane preparations from cells expressing nAChRs are incubated with a radiolabeled ligand (e.g., [³H]epibatidine or [³H]cytisine) and various concentrations of N-Acetylcytisine. Specific binding is determined, and Ki values are calculated from competition binding curves. Functional activity (partial agonism) is assessed using calcium flux assays or electrophysiological recordings in cells expressing nAChRs.
|
| Cell Assay |
For cellular studies, cells expressing nicotinic acetylcholine receptors (e.g., HEK293 cells transfected with nAChR subunits) are cultured in appropriate media. Cells are treated with N-Acetylcytisine at various concentrations, and receptor activation is measured using calcium-sensitive fluorescent dyes (e.g., Fluo-4) or by patch-clamp electrophysiology. The compound has a molecular formula of C₁₃H₁₆N₂O₂ and a molecular weight of 232.28 g/mol.
|
| Animal Protocol |
In vivo studies for N-Acetylcytisine would be conducted in rodent models of nicotine addiction. The compound would be administered via intraperitoneal injection or oral gavage. Behavioral assessments would include nicotine self-administration, conditioned place preference, or withdrawal symptom scoring. However, specific published protocols for this compound are not available.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for N-Acetylcytisine are not reported. The compound has a molecular formula of C₁₃H₁₆N₂O₂ and a molecular weight of 232.28 g/mol. As a cytisine derivative, it is expected to have moderate lipophilicity and potential for oral absorption and blood-brain barrier penetration. Pharmacokinetic studies would be required to determine parameters such as half-life, Cmax, and bioavailability.
|
| Toxicity/Toxicokinetics |
Toxicological data for N-Acetylcytisine are not reported. As a nicotinic receptor ligand, the compound may have dose-dependent effects on the nervous system. Cytisine and related alkaloids have been studied for their safety profiles in smoking cessation research. Comprehensive toxicology studies would be required before any therapeutic development. The compound should be handled with appropriate safety precautions.
|
| References | |
| Additional Infomation |
It has been reported that 11-acetyl-6-oxo-7,11-diazatricyclo[7.3.1.0<2,7>]tetane-2,4-diene has been discovered in Petteria ramentacea, and relevant data are available.
N-Acetylcytisine is a cytisine derivative that acts as a partial agonist at nicotinic acetylcholine receptors for smoking cessation research. Molecular formula: C₁₃H₁₆N₂O₂, molecular weight: 232.28. No clinical trials exist. For research use only. |
| Molecular Formula |
C13H16N2O2
|
|---|---|
| Molecular Weight |
232.27834
|
| Exact Mass |
232.121
|
| CAS # |
6018-52-6
|
| PubChem CID |
927586
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
0.1
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
17
|
| Complexity |
439
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(=O)N1C[C@@H]2C[C@H](C1)C3=CC=CC(=O)N3C2
|
| InChi Key |
CC(=O)N1C[C@@H]2C[C@H](C1)C3=CC=CC(=O)N3C2
|
| InChi Code |
WCRIKJOQMRFVPX-WDEREUQCSA-N
|
| Chemical Name |
(1R,9S)-11-acetyl-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3051 mL | 21.5257 mL | 43.0515 mL | |
| 5 mM | 0.8610 mL | 4.3051 mL | 8.6103 mL | |
| 10 mM | 0.4305 mL | 2.1526 mL | 4.3051 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
